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A BS TR AC T
BACKGROUND
The rate of unintended pregnancy in the United States is much higher than in 
other developed nations. Approximately half of unintended pregnancies are due to 
contraceptive failure, largely owing to inconsistent or incorrect use.
METHODS
We designed a large prospective cohort study to promote the use of long-acting 
reversible contraceptive methods as a means of reducing unintended pregnancies in 
our region. Participants were provided with reversible contraception of their choice 
at no cost. We compared the rate of failure of long-acting reversible contraception 
(intrauterine devices [IUDs] and implants) with other commonly prescribed contra-
ceptive methods (oral contraceptive pills, transdermal patch, contraceptive vaginal 
ring, and depot medroxyprogesterone acetate [DMPA] injection) in the overall co-
hort and in groups stratified according to age (less than 21 years of age vs. 21 years 
or older).
RESULTS
Among the 7486 participants included in this analysis, we identified 334 unin-
tended pregnancies. The contraceptive failure rate among participants using pills, 
patch, or ring was 4.55 per 100 participant-years, as compared with 0.27 among 
participants using long-acting reversible contraception (hazard ratio after adjust-
ment for age, educational level, and history with respect to unintended pregnancy, 
21.8; 95% confidence interval, 13.7 to 34.9). Among participants who used pills, 
patch, or ring, those who were less than 21 years of age had a risk of unintended 
pregnancy that was almost twice as high as the risk among older participants. 
Rates of unintended pregnancy were similarly low among participants using DMPA 
injection and those using an IUD or implant, regardless of age.
CONCLUSIONS
The effectiveness of long-acting reversible contraception is superior to that of con-
traceptive pills, patch, or ring and is not altered in adolescents and young women. 
(Funded by the Susan Thompson Buffet Foundation.)
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Unintended pregnancy is a major problem in the United States. Approxi-mately 3 million pregnancies per year — 
50% of all pregnancies — are unintended, and 
this rate is significantly higher than that in other 
developed countries.1 Unintended pregnancy in 
the United States results in 1.2 million abortions 
per year,2 has negative effects on women’s health 
and education and the health of newborns, and 
imposes a considerable personal burden as well 
as a financial burden on families and society.3 
Approximately half of unintended pregnancies 
result from contraceptive failure, usually owing 
to incorrect or inconsistent use of contraception, 
and the remainder are due to nonuse.4-6
The most commonly used contraceptive 
method in the United States is the oral contra-
ceptive pill.7 Because the pill requires daily com-
pliance, failure rates calculated on the basis of 
“perfect use” differ from real-world failure rates 
calculated on the basis of typical use. Annual 
failure rates with typical use of oral contracep-
tive pills are estimated at 9% for the general 
population, 13% for teenagers, and 30% or 
higher for some high-risk subgroups.4,8 Prior 
estimates of the failure rates with typical oral-
contraceptive use have relied on retrospective 
survey data, primarily from the National Survey 
of Family Growth.9
Long-acting reversible contraceptive methods, 
including intrauterine devices (IUDs) and sub-
dermal implants, are not user-dependent and 
have very low failure rates (less than 1%), which 
rival those with sterilization.9 Despite their 
proven safety in women and adolescents of all 
ages,10,11 IUDs are used by only 5.5% of women 
who use contraception in the United States.7 
Other developed countries, such as the United 
Kingdom and France, where IUDs are used more 
frequently, have rates of unintended pregnancy 
that are lower than those in the United States.12
Prospective data on contraceptive failure from 
a large number of women in the United States 
are limited. We analyzed data from a cohort of 
participants at risk for unintended pregnancy, 
who received contraceptive counseling and free 
contraception, to compare the rate of failure of 
long-acting reversible contraception (IUDs and 
implants) with the failure rates for other com-
monly prescribed contraceptive methods (pills, 
transdermal patch, vaginal ring, and depot me-
droxyprogesterone acetate [DMPA] injection).
ME THODS
STUDY ENROLLMENT
The Contraceptive CHOICE Project is a prospec-
tive cohort study with the primary goal of pro-
moting the use of long-acting reversible contra-
ceptive methods as a means of reducing 
unintended pregnancies.13 From August 2007 
through September 2011, we enrolled 9256 par-
ticipants at risk for unintended pregnancy. All 
participants chose a contraceptive method and 
received it at no cost. Study participants were a 
convenience sample of women and adolescents in 
the St. Louis region, recruited by means of refer-
rals from medical providers, newspaper reports, 
study flyers, and word of mouth.
The study protocol was approved by the local 
institutional review board before recruitment was 
initiated. All participants provided written in-
formed consent.
Eligible participants were 14 to 45 years of age, 
were not currently using a contraceptive method 
or were willing to switch to a new reversible con-
traceptive, had no desire for pregnancy for at least 
the next 12 months, were sexually active or were 
planning to become sexually active with a male 
partner during the next 6 months, resided in the 
St. Louis region, and spoke English or Spanish. 
Persons were excluded if they had undergone a 
hysterectomy or sterilization procedure.
STUDY DESIGN
Before enrollment in the study, all potential par-
ticipants were read a standardized script regard-
ing long-acting reversible contraceptive methods 
that stated that the two IUDs and the subdermal 
implant were the most effective methods of con-
traception (see the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org). 
If they were eligible for enrollment, participants 
received contraceptive counseling regarding all 
reversible contraceptive methods, including their 
effectiveness, side effects, risks, and benefits. Each 
participant was then provided with a reversible 
contraceptive method of her choice at no cost for 
3 years (first 5090 participants) or 2 years (re-
mainder of cohort). Participants were permitted 
to discontinue or switch methods as many times 
as desired during the follow-up period. A com-
prehensive baseline interview was performed, and 
participants were screened for sexually transmit-
ted infections.
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Participants were followed prospectively, with 
telephone interviews at 3 and 6 months and ev-
ery 6 months thereafter for the duration of fol-
low-up. Participants received a $10 gift card for 
every completed follow-up interview. In the base-
line and follow-up interviews, we collected com-
prehensive information on demographic charac-
teristics and reproductive history.
This analysis includes the first 7486 partici-
pants who used an IUD, implant, DMPA injection, 
pills, patch, or ring during the study. Periods of 
condom use or other contraceptive method use 
(e.g., diaphragm or natural family planning) were 
excluded from the analysis of contraceptive fail-
ure. At each survey, participants were asked about 
missed menses and possible pregnancy. Any par-
ticipant who thought she might be pregnant was 
asked to come in for urine pregnancy testing. A 
pregnancy log was used to record all pregnancies. 
Participants who had a pregnancy were asked if it 
was intended and what contraceptive method (if 
any) they were using at the time of conception. 
The conception date was estimated from the date 
of the last menstrual period or from the gesta-
tional-age assessment on ultrasonography. Con-
traceptive-method failure was defined as con-
ception that occurred during a period when the 
contraceptive method was used. If the participant 
stated that she had stopped using the method, 
this was listed as “no method” and was not con-
sidered a contraceptive-method failure. We ex-
cluded conception that occurred after a partici-
pant stopped using a method owing to a desire to 
conceive (intended pregnancy).








Age — yr 23.9±4.7 23.9±5.5 25.5±6.0
Race — no./total no. (%)†
Black 639/1519 (42.1) 122/176 (69.3) 2846/5750 (49.5)
White 752/1519 (49.5) 43/176 (24.4) 2471/5750 (43.0)
Other 128/1519 (8.4) 11/176 (6.3) 433/5750 (7.5)
Educational level — no./total no. (%)‡
High school or less 364/1527 (23.8) 90/175 (51.4) 2065/5778 (35.7)
Some college 684/1527 (44.8) 70/175 (40.0) 2423/5778 (41.9)
College degree or higher 479/1527 (31.4) 15/175 (8.6) 1290/5778 (22.3)
Monthly income — no./total no. (%)§
≤$1,600 1170/1467 (79.8) 162/175 (92.6) 4574/5707 (80.1)
>$1,600 297/1467 (20.2) 13/175 (7.4) 1133/5707 (19.9)
Receiving public assistance — no. (%)¶
No 1218 (79.8) 106 (60.2) 3468 (60.0)
Yes 309 (20.2) 70 (39.8) 2313 (40.0)
Trouble paying basic expenses — no. (%)‖
No 969 (63.5) 79 (44.9) 3522 (60.9)
Yes 558 (36.5) 97 (55.1) 2259 (39.1)
Health insurance — no./total no. (%)**
None 631/1507 (41.9) 102/176 (58.0) 2304/5748 (40.1)
Private 796/1507 (52.8) 55/176 (31.3) 2438/5748 (42.4)
Public 80/1507 (5.3) 19/176 (10.8) 1006/5748 (17.5)
Parity — no. (%)
0 1088 (71.3) 90 (51.1) 2384 (41.2)
1 279 (18.3) 34 (19.3) 1530 (26.5)
2 115 (7.5) 32 (18.2) 1152 (19.9)
≥3 45 (2.9) 20 (11.4) 715 (12.4)
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Information about periods of contraceptive 
use, including start and stop dates, was collected 
from three sources: scheduled telephone inter-
views; pharmacy data obtained from the partner 
pharmacy where participants obtained pills, 
patch, or ring; and the participant contraceptive-
method log, which documented in our research 
records when the participant initiated or discon-
tinued use of a method or switched to another 
method (i.e., insertion or removal of an IUD or 
implant; receipt of an initial pill supply, patch, 
or ring; and DMPA injection). A participant was 
considered to have used DMPA for the 3-month 
interval after a record of an injection. In the case 
of expulsion of an IUD, if the participant knew 
the device had fallen out and she became preg-
nant, the unintended pregnancy was attributed 
to “no method” (unless an alternative method 
was used). However, if the participant was un-
aware that the device had fallen out, the preg-
nancy was attributed to IUD failure.
At each follow-up interview, we asked partici-
pants if they were still using the same contra-
ceptive method, if they had stopped using it, and 
their start and stop dates. For participants who 
did not answer these questions, we reviewed 
their contraceptive-method log and pharmacy-
refill records to confirm their status. If the data 
from the log, follow-up interview, and pharmacy 
records were conflicting, we used the data source 
with the most detailed information. If multiple 
contraceptive methods were used simultaneously 
(e.g., pills and condoms), the most effective meth-
od was assigned.9 Data from participants who 
were lost to follow-up were censored at the time 









Previous unintended pregnancies — no./ 
total no. (%)††
0 829/1522 (54.5) 61/176 (34.7) 1839/5770 (31.9)
1 393/1522 (25.8) 44/176 (25.0) 1566/5770 (27.1)
2 159/1522 (10.4) 36/176 (20.5) 1064/5770 (18.4)
≥3 141/1522 (9.3) 35/176 (19.9) 1301/5770 (22.5)
Previous abortions — no. (%)
0 1072 (70.2) 106 (60.2) 3672 (63.5)
1 331 (21.7) 41 (23.3) 1294 (22.4)
2 87 (5.7) 21 (11.9) 530 (9.2)
≥3 37 (2.4) 8 (4.5) 285 (4.9)
History of STI — no. (%)‡‡
No 1008 (66.0) 90 (51.1) 3397 (58.8)
Yes 519 (34.0) 86 (48.9) 2384 (41.2)
* Plus–minus values are means (±SD). P<0.001 for comparisons of the three groups. The total number of participants 
does not equal 7486 because 2 participants chose natural family planning as their contraceptive method at baseline 
but then went on to choose another method later in the study. Percentages may not necessarily add up to 100 be-
cause of rounding. DMPA denotes depot medroxyprogesterone acetate; LARC long-acting reversible contraception 
(intrauterine device or implant); PPR pill, patch, or ring; and STI sexually transmitted infection.
† Race was self-reported. Data were missing for 8 participants in the PPR group and 31 in the LARC group.
‡ Data on educational level were missing for 1 participant in the DMPA group and 3 in the LARC group.
§ Data on monthly income were missing for 60 participants in the PPR group, 1 in the DMPA group, and 74 in the 
LARC group.
¶  “Receiving public assistance” was defined as self-reported current receipt of food stamps; vouchers from the supple-
mentary nutritional program for women, infants, and children (WIC); welfare; or unemployment benefits.
‖ “Trouble paying basic expenses” was defined as self-reported difficulty in paying for transportation, housing, health or 
medical care, or food.
** Data on health insurance were missing for 20 participants in the PPR group and 33 in the LARC group.
†† Data on previous unintended pregnancies were missing for 5 participants in the PPR group and 11 in the LARC group.
‡‡ Data are based on a self-reported history of chlamydia infection, gonorrhea, syphilis, trichomoniasis, genital herpes, 
human papillomavirus infection, or human immunodeficiency virus infection.
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STUDY OUTCOMES
The primary outcome of the study was contracep-
tive failure. We also evaluated pregnancy rates by 
age group as a secondary outcome. Our hypothe-
ses were, first, that participants using pills, patch, 
or ring would have higher rates of contraceptive 
failure than those using long-acting methods 
and, second, that the rate of failure with the pills, 
patch, or ring would be higher among younger 
women and adolescents (<21 years of age) than 
among older women.
STATISTICAL ANALYSIS
Statistical analyses were performed with the use 
of Stata software, version 11 (StataCorp). The sig-
nificance level (alpha) was set at 0.05. To describe 
the demographic characteristics of the study par-
ticipants, we used means, standard deviations, 
frequencies, and percentages. For the compari-
son among users of different contraceptive meth-
ods, Student’s t-test was used for continuous 
variables and a chi-square test was performed for 
categorical data.
We measured distinct segments of contracep-
tive-method use that represented the months each 
participant used the method. We calculated par-
ticipant-years of use for each method by captur-
ing all segments of use. Thus, participants who 
switched methods contributed distinct segments 
to multiple methods. Cox proportional-hazard 
models were used to estimate the hazard ratios 
for unintended pregnancy with different methods. 
We used clustering of variance–covariance estima-
tion methods to account for the effect of correla-
tion among different periods of contraceptive use 
and multiple pregnancies for the same participant. 
Effect modification was assessed by including an 
interaction term between the method and the co-
variate of interest in the model. The final multi-
variate model included adjustment for confounders 
and other variables with the potential to influence 
the outcome.
Table 2. Baseline Characteristics of Participants with No Pregnancy and Those with an Unintended Pregnancy 






(N = 334) P Value
Age — yr 25.2±5.8 23.6±5.1 <0.001
Race — no./total no. (%)† <0.001
Black 3408/7113 (47.9) 200/334 (59.9)
White 3163/7113 (44.5) 104/334 (31.1)
Other 542/7113 (7.6) 30/334 (9.0)
Educational level — no./total no. (%)‡ <0.001
High school or less 2356/7148 (33.0) 163/334 (48.8)
Some college 3044/7148 (42.6) 134/334 (40.1)
College degree or higher 1748/7148 (24.5) 37/334 (11.1)
Monthly income — no./total no. (%)§ 0.01
≤$1,600 5629/7025 (80.1) 279/326 (85.6)
>$1,600 1396/7025 (19.9) 47/326 (14.4)
Receiving public assistance — no. (%) 0.002
No 4606 (64.4) 187 (56.0)
Yes 2546 (35.6) 147 (44.0)
Trouble paying basic expenses — no. (%) <0.001
No 4409 (61.6) 162 (48.5)
Yes 2743 (38.4) 172 (51.5)
Health insurance — no./total no. (%)¶ <0.001
None 2872/7102 (40.4) 165/331 (49.8)
Private 3179/7102 (44.8) 111/331 (33.5)
Public 1051/7102 (14.8) 55/331 (16.6)
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R ESULT S
CHARACTERISTICS OF THE PARTICIPANTS
From August 2007 through May 2011, a total of 
8445 participants enrolled in the study, and 7486 
met the eligibility criteria for this analysis. We 
identified 334 unintended pregnancies; of these, 
156 were attributed to IUD, implant, DMPA injec-
tion, pill, patch, or ring failure. Table 1 summa-
rizes the demographic and reproductive charac-
teristics of the participants, according to the 
method of contraception chosen at baseline. Par-
ticipants who chose pills, patch, or ring at enroll-
ment, as compared with those who chose other 
contraceptive methods, were more likely to be 
nulliparous, more likely to have private health 
insurance, and less likely to have had a previous 
unintended pregnancy, abortion, or sexually trans-
mitted infection. Participants who chose DMPA 
injections were more likely to be black, to be less 
educated, to have a lower socioeconomic status, to 
have no health insurance, and to have a history 
of a sexually transmitted infection. Participants 
who chose an IUD or implant were more likely to 
be older, to have public health insurance, and to 
have higher parity.
Table 2 shows the baseline characteristics of 
participants who had no pregnancy and those who 
had an unintended pregnancy during the study 
period. Participants who had an unintended preg-
nancy were younger, less educated, more likely to 
be black, and more likely to rely on public assis-
tance or to report difficulty paying for basic ex-
penses. They were also more likely to have a 








(N = 334) P Value
Parity — no. (%)  0.002
0 3436 (48.0) 127 (38.0)
1 1738 (24.3) 106 (31.7)
2 1239 (17.3) 60 (18.0)
≥3 739 (10.3) 41 (12.3)
Previous unintended pregnancies — no./ 
total no. (%)‖ <0.001
0 2664/7137 (37.3) 66/333 (19.8)
1 1896/7137 (26.6) 107/333 (32.1)
2 1195/7137 (16.7) 64/333 (19.2)
≥3 1382/7137 (19.4) 96/333 (28.8)
Previous abortions — no. (%) <0.001
0 4661 (65.2) 190 (56.9)
1 1584 (22.1) 82 (24.6)
2 592 (8.3) 47 (14.1)
≥3 315 (4.4) 15 (4.5)
History of STI — no. (%) <0.001
No 4337 (60.6) 159 (47.6)
Yes 2815 (39.4) 175 (52.4)
* Plus–minus values are means (±SD). Percentages may not add up to 100 because of rounding.
† Data on race were missing for 39 participants in the no-pregnancy group.
‡ Data on educational level were missing for 4 participants in the no-pregnancy group.
§ Data on monthly income were missing for 127 participants in the no-pregnancy group and 8 in the unintended- 
pregnancy group.
¶ Data on health insurance were missing for 50 participants in the no-pregnancy group and 3 in the unintended- 
pregnancy group.
‖ Data on previous unintended pregnancies were missing for 15 participants in the no-pregnancy group and 1 in the  
unintended-pregnancy group.
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CONTRACEPTIVE FAILURE RATES
Figure 1 shows the cumulative percentage of 
participants with a contraceptive failure at 1, 2, 
or 3 years, according to the contraceptive method. 
At all three time points, participants using pills, 
patch, or ring had higher rates of unintended preg-
nancy than those using long-acting reversible con-
traception. Failure rates in the group of participants 
who used the pills, patch, or ring were 4.8%, 7.8%, 
and 9.4% in years 1, 2, and 3, respectively; the cor-
responding rates in the group using IUDs or im-
plants were 0.3%, 0.6%, and 0.9% (P<0.001). The 
failure rates among participants who used DMPA 
injections were similar to those among participants 
who used IUDs or implants (0.1%, 0.7%, and 0.7% 
for years 1, 2, and 3, respectively; P = 0.96).
Table 3 shows the risks of contraceptive failure 
associated with the chosen contraceptive meth-
ods and other characteristics of the participants. 
The failure rate for the pills, patch, or ring was 
4.55 per 100 participant-years, as compared with 
0.22 for DMPA injections and 0.27 for IUDs or 
implants (P<0.001 for both comparisons). The 
risk of unintended pregnancy among participants 
using pills, patch, or ring was markedly higher 
than that among participants who used long-
acting reversible contraception (hazard ratio after 
adjustment for age, educational level, and number 
of previous unintended pregnancies, 21.8; 95% 
confidence interval [CI], 13.7 to 34.9).
To determine whether participants less than 
21 years of age who used pills, patch, or ring had 
a higher rate of unintended pregnancy than older 
women using these methods, we stratified our 
sample according to age. Participants less than 
21 years of age who were using pills, patch, or ring 
had almost twice the risk of unintended pregnancy 
as older women (hazard ratio after adjustment for 
educational level and history with respect to unin-
tended pregnancy, 1.9; 95% CI, 1.2 to 2.8) (Fig. 2). 
The rate of contraceptive failure did not differ sig-
nificantly according to age group among partici-
pants who used DMPA injections or among those 
who used long-acting reversible contraception, but 
numbers for these analyses were smaller and the 
power to detect differences was low.
DISCUSSION
We found that participants using oral contracep-
tive pills, a transdermal patch, or a vaginal ring had 
a risk of contraceptive failure that was 20 times 
as high as the risk among those using long-acting 
reversible contraception. The failure rate among 
participants who used pills, patch, or ring was 
4.55 per 100 participant-years, as compared with 
0.22 for those who used DMPA and 0.27 for those 
who used an IUD or implant. Participants less than 
21 years of age who used pills, patch, or ring had 
almost twice the risk of unintended pregnancy as 
older women using the same methods.
Our findings on contraceptive-method effec-
tiveness are supported by previous studies. The 
National Survey of Family Growth estimates that 
9% of women using oral contraceptive pills will 
have an unintended pregnancy within the first 
year, as compared with only 0.001%, 0.14%, and 
0.7% of women who use the subdermal implant, 
levonorgestrel IUD, or copper IUD, respectively.8 
However, these data were derived from retrospec-
tive surveys that asked women to recall their con-
traceptive use and pregnancies over the past (on 
average) 3.75 years.4,8 The failure rate for DMPA 
injections in our study is lower than other re-
ported rates because we categorized a pregnancy 
as a contraceptive failure only in users who had 
returned for injections; thus, these rates repre-
sent “perfect use” rather than typical use, given 
that more than 40% of women who use DMPA 
will discontinue use in the first year.10
Half of all pregnancies in the United States 
































Figure 1. Cumulative Percentage of Participants Who Had a Contraceptive 
Failure at 1, 2, or 3 Years, According to Contraceptive Method.
Bars depict the cumulative percentage of participants who had a contra-
ceptive failure with long-acting reversible contraception (LARC), depot 
 medroxyprogesterone acetate (DMPA), or pill, patch, or ring (PPR) at 1, 2, 
or 3 years. Participants using PPR had significantly more unintended preg-
nancies than those using LARC (P<0.001) or DMPA (P<0.001).
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traceptive failure.1,4 Among women using revers-
ible contraception, 70% use pills or condoms,7 and 
one in every eight users of reversible methods will 
have a contraceptive failure in the first year.4 We 
have previously shown in the same cohort that 
participants using long-acting reversible methods 
of contraception have higher continuation rates 
(>80%) at 12 months than participants using 
other reversible methods (range, 49 to 57%).10 If 
more women used the highly effective, long-
acting reversible methods, we would expect a 
decrease in the number of unintended pregnan-
cies, because there would be more women con-
tinuing to use contraception.14
There are few contraindications to long-acting 
reversible contraception; almost all women are 
eligible for an IUD or implant. The U.S. Medical 
Eligibility Criteria for Contraceptive Use provides 
guidelines from the Centers for Disease Control 
and Prevention that are endorsed by the American 
College of Obstetricians and Gynecologists.15 
Modern IUDs do not carry an increased risk of 
pelvic inflammatory disease after the first 20 days 
following insertion.16 Women who are at average 
risk for sexually transmitted infections are good 
candidates for IUDs, as long as they do not have 
cervicitis at the time of insertion.15 IUDs and im-
plants are also associated with acceptable adverse-
event rates among adolescents and nulliparous 
women; satisfaction rates among adolescents and 
young women using the levonorgestrel IUD or 
the implant are similar to the rates among older 
women.10,11,17 Implants also have very few contra-
indications. Unpredictable bleeding is the most 
common side effect and the most frequent rea-
son for discontinuation.18
In our age-stratified analysis, participants less 
than 21 years of age who used pills, patch, or 
ring had a significantly increased risk of contra-
ceptive failure, as compared with older women; in 












LARC 21 7655 0.27 1.00 1.00
DMPA 2  902 0.22 0.72 (0.17–3.09) 0.70 (0.16–3.03)
PPR 133 2924 4.55 16.05 (10.19–25.29) 21.84 (13.67–34.88)
Age
<21 yr 1.83 (1.25–2.69)
≥21 yr 1.00
Educational level
High school or less 1.00
Some college 0.73 (0.52–1.03)






* The remaining 178 of the 334 unintended pregnancies were attributed to failure of condoms, withdrawal, or any form of contraception that 
was not included in this analysis. Only periods of index contraceptive-method use (pills, patch, ring, DMPA injection, implant, or intrauter-
ine device) and associated pregnancies were included in this analysis.
† Hazard ratios were adjusted for age, educational level, and number of previous unintended pregnancies.
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contrast, younger and older participants who 
used an IUD, implant, or DMPA had similarly low 
risks of pregnancy. Other study data have also in-
dicated that the risk of contraceptive failure with 
pills is more than twice as high among teenagers 
as it is among women older than 30 years of age.4 
The increased risk of contraceptive failure among 
adolescents, as compared with women, may reflect 
lower adherence to a daily pill regimen. In a sam-
ple of girls who were 14 to 17 years of age and 
who were seeking primary care, 25% of those who 
used oral contraceptive pills reported that they 
missed taking two or more pills per cycle.19 These 
data underscore the potential benefits of offering 
adolescents long-acting reversible contraception 
(which does not require daily, weekly, or monthly 
compliance) to reduce unintended pregnancies in 
this high-risk age group.
The strengths of our study include the prospec-
tive design of the Contraceptive CHOICE Project, 
a large sample, multiple sources of data for as-
sessment of contraceptive use (including objective 
pharmacy data), and a low rate of loss to follow-up. 
There are few prospective reports in the medical 
literature that assess the effectiveness of contra-
ceptive methods in large, diverse U.S. populations. 
One limitation of our study is the nonrandom-
ized design, resulting in potential confounding 
of the association between contraceptive method 
and outcomes by characteristics associated with 
the choice of contraception. However, women 
who chose long-acting methods tended to be 
less educated and to have higher rates of previ-
ous pregnancies and abortions — features ex-
pected to be associated with higher (not lower) 
rates of unintended pregnancy. In addition, study 
participants were a selected group (at high risk 
for unintended pregnancy and willing to begin 
using a new method). Insofar as women may be 
more likely to consistently use a method they 
have chosen than one they have been assigned, 
the compliance rates may be higher, and failure 
rates lower, than would be expected in a ran-
domized trial. Another potential limitation of our 
study is generalizability. Participants were at high 
risk for unintended pregnancy and had to be will-
ing to switch to a new contraceptive method, 
which may have resulted in overestimation of con-
traceptive failure rates, as compared with rates in 
the general U.S. population. However, contracep-
tion was provided at no cost, which may have im-
proved adherence and led to an underestimation of 
failure rates, counterbalancing this potential bias.
In conclusion, we found that long-acting revers-
ible methods of contraception (IUDs or implants) 
were more effective in preventing unintended preg-
nancy than contraceptive pills, patch, or ring and 
worked well regardless of age.
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Figure 2. Probability of Not Having an Unintended Pregnancy, According to 
Contraceptive Method and Age.
Survival curves show the probability of not having an unintended pregnan-
cy, stratified according to age group. LARC methods were the most effec-
tive, and failure rates did not vary according to age (P = 0.49). PPR methods 
were less effective, and failure rates in participants younger than 21 years 
old were twice as great as in women 21 years of age or older (P = 0.02).
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